corporate-strategy
(18)
The Tiny Firm Built for the Moment Before a CEO Speaks
Scale sells something executives rarely admit they need: a second mind in the room when every sentence carries consequences. Its founders learned the trade in politics, professional tennis, Fortune 500 boardrooms and one of corporate history's loudest failed IPOs.
The Firm You Call on Sunday Night
One Strategy Group bet that CEOs no longer wanted an agency pyramid between the problem and the person solving it. Four years, three acquisitions and one global network later, the bet has become a business model.
The Ingram Group and the Problem Behind the Problem
A Nashville consultancy built its business on a campaign habit: diagnose the real obstacle, map the people who can move it, and only then decide whether the answer is lobbying, communications, coalition-building - or something else.
The Consultants Who Have Already Sat in Your Chair
Hawksbill Group sells an unusual consulting product: the scar tissue of people who ran factories, regions, policy shops and public companies before they began giving advice.
Mario Carvajal Has Spent 17 Years Turning Technical Detail Into Corporate Direction
He arrived at AvePoint through engineering and stayed long enough to help explain its next era. Now Mario Carvajal works where product architecture, corporate strategy and the public story meet.
Kristine Ball Knows What Happens After the Science Gets Interesting
She began in audit, learned biotech from the inside, and became the operator companies call when science must survive contact with money, markets and momentum.
Matthew Graybill Is Marketing the Space Between the Machines
After a dozen years moving from product marketing to corporate strategy, Matthew Graybill arrived at GE HealthCare with a deceptively difficult brief: make a vast cardiovascular portfolio feel like one connected idea.
Bharath Ram Has Spent 35 Years Making New Technology Make Business Sense
From opening a two-person encryption office in Tokyo to shaping enterprise data strategy in the AI era, Bharath Ram's career is a study in translating hard technology into partnerships, markets and durable value.
Jeffrey Amling and the Discipline of Saying No
For four decades, Jeffrey Amling has worked where judgment matters more than motion. His career links Wall Street's media deal boom, FTI Consulting's selective acquisition strategy, and a patient second life breeding racehorses built for the long run.
Chris Scherman Is Learning to Read the Energy Map Before It Is Drawn
A lawyer moved from contracts to corporate strategy. At Pembina, Chris Scherman now works where long-lived infrastructure, customer demand and the next version of the energy map meet.
The Business Where the Product Is a Room Full of People Who Cannot Talk Elsewhere
World 50 built a business around a C-suite paradox: the higher an executive rises, the fewer people they can speak to freely. Its answer is a paid, invitation-only network where candor - carefully curated and kept off the record - is the product.
Catherine Kniker
Catherine Kniker began by decoding crashed computers. Now the Irish-born PTC executive is working on a larger systems problem: helping manufacturers connect product data, business strategy and sustainability before the first part reaches the factory floor.
Chris McNulty
Chris McNulty is the interim CEO of Ring Therapeutics, a Cambridge, Massachusetts biotech developing genetic medicines that use commensal anelloviruses as delivery vectors. An MIT-trained engineer with a Harvard MBA, he joined Ring in May 2023 as Chief Financial Officer and Head of Corporate Strategy and stepped up to lead the company in December 2024. Over more than 15 years in pharma and biotech finance, he has closed financing transactions worth more than $300 million across companies including VBI Vaccines, InVivo Therapeutics, Repligen, and Genzyme.
Jennifer Bergheiser
Jennifer Bergheiser is the Chief Business Officer of eGenesis, the Cambridge biotech turning gene-edited pig organs into a real answer to the transplant waitlist. She runs corporate strategy and all portfolio and commercial development, drawing on more than two decades across big pharma, venture capital, and consulting. Her resume runs from screening deals at Domain Associates to steering the blockbuster autoimmune drug Stelara at Centocor/Johnson & Johnson. At eGenesis she helps commercialize one of medicine's boldest bets: organs grown in pigs, edited dozens of times over, transplanted into living humans.
Darren Hakeman
Darren Hakeman is the CEO of Genesis Digital LLC, the company behind Kartra, WebinarJam, and EverWebinar - software tools powering the creator economy for 25,000+ entrepreneurs worldwide. A Stanford-trained electrical engineer, Hakeman spent decades in enterprise tech - from RFID logistics at Savi Technology to scaling 8x8's ARR 5x to over $500 million through eight acquisitions - before stepping into the CEO role at Genesis Digital in April 2024, where the company has processed over $1 billion in transactions for small business owners seeking financial freedom.
Elaine Cheung
Elaine Cheung is Chief Business Officer at Moonwalk Biosciences, a South San Francisco biotech backed by $57 million in funding and co-founded by CRISPR pioneer Feng Zhang and former Illumina CTO Alex Aravanis. With 20+ years navigating the inflection points of genomic medicine - from spinning GRAIL out of Illumina, helping architect its $900M+ Series B, and steering Lyell Immunopharma through its IPO - Cheung brings a rare combination of scientific literacy and deal-making precision. At Moonwalk, she is helping build the business infrastructure for a company that has pivoted from epigenetic editing to siRNA-based therapeutics targeting adipose biology and obesity.
Sofia Touami
Sofia Touami, Ph.D., is the Chief Business Officer of Lycia Therapeutics, a South San Francisco biotech pioneering lysosomal targeting chimeras (LYTACs) - a platform invented by Nobel laureate Carolyn Bertozzi to degrade disease-causing extracellular proteins. A trained organic chemist who earned her Ph.D. at Stanford and did postdoctoral work at The Scripps Research Institute, Touami has built a career as one of biotech's sharpest dealmakers, having orchestrated major transactions including Frontier Medicines' landmark global collaboration with AbbVie before joining Lycia in July 2023. She helped close Lycia's oversubscribed $106.6 million Series C in May 2024, positioning the company to bring its LYTAC-based autoimmune therapies into clinical trials.
Diana Peng Bockus
Diana Peng Bockus is the Chief Executive Officer of NGM Biopharmaceuticals, a South San Francisco biotech developing first-in-class medicines for liver disease, oncology, and ophthalmology. Appointed CEO in April 2025, she joined the company in 2020 to lead business development and restructured a pivotal Merck partnership that freed NGM to build a wholly owned pipeline. A Stanford and Wharton graduate with roots in management consulting at Bain & Company, she now steers a privately held biotech backed by $515M in total funding, focused on rare diseases like primary sclerosing cholangitis and hyperemesis gravidarum.